CT:CRDL Cardiol Therapeutics Inc. Class A

Cardiol Therapeutics Inc. focuses on the production of pharmaceutical cannabidiol (CBD) products. The company is also developing various therapies for heart diseases, including acute myocarditis and other causes of heart failure. Its lead product is CardiolRx, a pharmaceutically-produced CBD formulation. In addition, it is developing nanotechnology to deliver pharmaceutical CBD and other anti-inflammatory drugs directly to sites of inflammation in the heart that are associated with heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is based in Oakville, Canada.

This company cross-lists their shares on a U.S. stock exchange. See the related U.S. symbol CRTPF.

1.47 CAD
As of 09/23/2022

Security Information
Category1:  Global Equity
Category2:  Common stocks
Category3:  Developed markets ex-US
GICS sector:  Unknown
Industry:  Drug Manufacturers-Specialty &
Index country:  Canada
Country of incorporation:  Canada
IPO date:  01/01/1900
Stock exchange:    Toronto Stock Exchange
Exchange country:   Canada
Market cap:   94,126,760 CAD
Current dividend yield:   0.00%
Sedol:      BHZT969

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy